English French German Italian Spanish


TIRCON Kick-off Group

NBIA research took a big leap forward with the European Union’s November 2011 award of a collaborative four-year grant worth $7.02 million in U.S. dollars, or 5.2 million Euros.

Treat Iron-Related Childhood-Onset Neurodegeneration (TIRCON) is a research consortium consisting of 13 partners from eight countries. Researchers consider the collaborative effort to be historic for the NBIA community and are excited about the grant’s potential to lead to new insights and potential treatments for NBIA-affected individuals.

The goals of TIRCON are:

  1. Set up an international NBIA patient registry
  2. Establish a biobank
  3. Develop biomarkers for the disease
  4. Conduct a randomized clinical trial of the iron-chelating drug Deferiprone in PKAN
  5. Develop pantethine derivatives for treating PKAN

Please see the brochures here for more information on TIRCON or visit the website. For a listing of TIRCON funded publications, please go to http://tircon.eu/public-outreach/publications.





Seventh Framework Programme


FP7 (277984-2)






Text Size

TIRCON Information

TIRCON Leaflet

General information about TIRCON.

TIRCON Clinical Study

A Deferiprone-trial in patients with Pantothenate Kinase-Associated Neurodegeneration (PKAN).
Information Leaflet





Connect with Us

Researchers, Clinicians & Other Professionals

Connect with Us

Connect with Us

Donate Now

Sign-up for our Newsletter